Government Schemes and Policy · 13 November 2026
NPPA Orders Strict Monitoring of Trade Margin Rationalisation on 137 Non-Scheduled Anti-Cancer Drugs
Exam-focused facts from the 13 November 2026 current affairs briefing.
Key facts
- The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, directed strict monitoring of Trade Margin Rationalisation (TMR) on 137 non-scheduled anti-cancer drugs, notified by Gazette Order dated 17 October 2026, with revised prices effective from 9 November 2026.
- State Drug Controllers must monitor compliance by manufacturers, dealers, hospitals and medical institutions so that revised MRPs benefit patients, and must submit Action Taken Reports to NPPA by 16 November 2026.
- Violations may attract overcharging proceedings under the provisions of DPCO, 2013.
- Revised price lists, based on company submissions up to 11 November 2026, are available on the NPPA website and the Pharma Sahi Daam app/portal.
- Overcharging or medicine shortage complaints can be reported via the Pharma Sahi Daam app/portal, the NPPA helpline 1800-111-255, or email monitoring-nppa[at]gov[dot]in.